Targeted therapies for epithelial cancers: in vivo efficacy of the BCL-2/BCL-XL inhibitor 2-MeAA.
Schwartz
Pamela S
PS
Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Hockenbery
David M
DM
D000968:Antimycin A / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D045744:Cell Line, Tumor; D006801:Humans; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors*; D051020:bcl-X Protein / Q000037:antagonists & inhibitors*
C522799:2-methoxyantimycin; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein; D000968:Antimycin A